CC-115

/static/temp/default.svg Search structure
Synonyms
Status
Molecule Category UNKNOWN
UNII FII75TFH5L

Structure

InChI Key GMYLVKUGJMYTFB-UHFFFAOYSA-N
Smiles CCN1C(=O)CNc2ncc(-c3ccc(-c4nc[nH]n4)nc3C)nc21
InChI
InChI=1S/C16H16N8O/c1-3-24-13(25)7-18-15-16(24)22-12(6-17-15)10-4-5-11(21-9(10)2)14-19-8-20-23-14/h4-6,8H,3,7H2,1-2H3,(H,17,18)(H,19,20,23)

Bioactivity

Mechanism of Action Action Reference
DNA-dependent protein kinase inhibitor INHIBITOR PubMed
Protein: Serine/threonine-protein kinase mTOR
Description: Serine/threonine-protein kinase mTOR
Organism : Homo sapiens
P42345 ENSG00000198793
Protein: DNA-dependent protein kinase
Description: DNA-dependent protein kinase catalytic subunit
Organism : Homo sapiens
P78527 ENSG00000253729
Assay Description Organism Bioactivity Reference
Inhibition of mTORC2 in human PC3 cells assessed as inhibition of AKT phosphorylation at S473 after 1 hr Homo sapiens 22.0 nM
Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay Homo sapiens 21.0 nM
Inhibition of mTORC1 in human PC3 cells assessed as inhibition of S6 phosphorylation after 1 hr Homo sapiens 23.0 nM
Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 72 hrs Homo sapiens 138.0 nM
In vivo inhibition of mTORC1 in human PC3 cells xenografted in CB17 SCID mouse assessed as inhibition of S6 phosphorylation at 10 mg/kg, po measured at 1 hr relative to vehicle-treated control Mus musculus 85.0 %
In vivo inhibition of mTORC1 in human PC3 cells xenografted in CB17 SCID mouse assessed as inhibition of S6 phosphorylation at 10 mg/kg, po measured at 3 hrs relative to vehicle-treated control Mus musculus 91.0 %
In vivo inhibition of mTORC1 in human PC3 cells xenografted in CB17 SCID mouse assessed as inhibition of S6 phosphorylation at 10 mg/kg, po measured at 6 hrs relative to vehicle-treated control Mus musculus 94.0 %
In vivo inhibition of mTORC1 in human PC3 cells xenografted in CB17 SCID mouse assessed as inhibition of S6 phosphorylation at 10 mg/kg, po measured at 10 hrs relative to vehicle-treated control Mus musculus 94.0 %
In vivo inhibition of mTORC1 in human PC3 cells xenografted in CB17 SCID mouse assessed as inhibition of S6 phosphorylation at 10 mg/kg, po measured at 24 hrs relative to vehicle-treated control Mus musculus 93.0 %
In vivo inhibition of mTORC1 in human PC3 cells xenografted in CB17 SCID mouse assessed as inhibition of Akt phosphorylation at S473 at 10 mg/kg, po measured at 1 hr relative to vehicle-treated control Mus musculus 88.0 %
In vivo inhibition of mTORC1 in human PC3 cells xenografted in CB17 SCID mouse assessed as inhibition of Akt phosphorylation at S473 at 10 mg/kg, po measured at 3 hrs relative to vehicle-treated control Mus musculus 88.0 %
In vivo inhibition of mTORC1 in human PC3 cells xenografted in CB17 SCID mouse assessed as inhibition of Akt phosphorylation at S473 at 10 mg/kg, po measured at 6 hrs relative to vehicle-treated control Mus musculus 87.0 %
In vivo inhibition of mTORC1 in human PC3 cells xenografted in CB17 SCID mouse assessed as inhibition of Akt phosphorylation at S473 at 10 mg/kg, po measured at 10 hrs relative to vehicle-treated control Mus musculus 86.0 %
In vivo inhibition of mTORC1 in human PC3 cells xenografted in CB17 SCID mouse assessed as inhibition of Akt phosphorylation at S473 at 10 mg/kg, po measured at 24 hrs relative to vehicle-treated control Mus musculus 78.0 %
In vivo inhibition of mTORC1 in human PC3 cells xenografted in CB17 SCID mouse assessed as inhibition of S6 phosphorylation at 1 mg/kg, po measured at 1 hr relative to vehicle-treated control Mus musculus 85.0 %
In vivo inhibition of mTORC1 in human PC3 cells xenografted in CB17 SCID mouse assessed as inhibition of S6 phosphorylation at 1 mg/kg, po measured at 3 hrs relative to vehicle-treated control Mus musculus 89.0 %
In vivo inhibition of mTORC1 in human PC3 cells xenografted in CB17 SCID mouse assessed as inhibition of S6 phosphorylation at 1 mg/kg, po measured at 6 hrs relative to vehicle-treated control Mus musculus 83.0 %
In vivo inhibition of mTORC1 in human PC3 cells xenografted in CB17 SCID mouse assessed as inhibition of S6 phosphorylation at 1 mg/kg, po measured at 10 hrs relative to vehicle-treated control Mus musculus 79.0 %
In vivo inhibition of mTORC1 in human PC3 cells xenografted in CB17 SCID mouse assessed as inhibition of S6 phosphorylation at 1 mg/kg, po measured at 24 hrs relative to vehicle-treated control Mus musculus 0.0 %
In vivo inhibition of mTORC1 in human PC3 cells xenografted in CB17 SCID mouse assessed as inhibition of Akt phosphorylation at S473 at 1 mg/kg, po measured at 1 hr relative to vehicle-treated control Mus musculus 80.0 %
In vivo inhibition of mTORC1 in human PC3 cells xenografted in CB17 SCID mouse assessed as inhibition of Akt phosphorylation at S473 at 1 mg/kg, po measured at 3 hrs relative to vehicle-treated control Mus musculus 65.0 %
In vivo inhibition of mTORC1 in human PC3 cells xenografted in CB17 SCID mouse assessed as inhibition of Akt phosphorylation at S473 at 1 mg/kg, po measured at 6 hrs relative to vehicle-treated control Mus musculus 70.0 %
In vivo inhibition of mTORC1 in human PC3 cells xenografted in CB17 SCID mouse assessed as inhibition of Akt phosphorylation at S473 at 1 mg/kg, po measured at 10 hrs relative to vehicle-treated control Mus musculus 65.0 %
In vivo inhibition of mTORC1 in human PC3 cells xenografted in CB17 SCID mouse assessed as inhibition of Akt phosphorylation at S473 at 1 mg/kg, po measured at 24 hrs relative to vehicle-treated control Mus musculus 19.0 %
Inhibition of recombinant human cFMS at 3 uM relative to control Homo sapiens 57.0 %
Inhibition of human DNA PK Homo sapiens 15.0 nM
Inhibition of PI3Kalpha (unknown origin) Homo sapiens 850.0 nM
Inhibition of ATR (unknown origin) at 30 uM relative to control Homo sapiens 50.0 %
Inhibition of PDE3 (unknown origin) at 10 uM relative to control Homo sapiens 50.0 %
Inhibition of PDE3 (unknown origin) Homo sapiens 630.0 nM
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging Homo sapiens 96.61 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 5.867 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 1.21 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 1.21 %
Enzymatic assay of human HDAC6 with commercial peptide substrate Homo sapiens -10.04 %
Enzymatic assay of human HDAC6 with custom peptide substrate Homo sapiens 0.29 %

Cross References

Resources Reference
ChEMBL CHEMBL3545426
FDA SRS FII75TFH5L
PubChem 58298318
CONTENTS